Format

Send to

Choose Destination
Aging Clin Exp Res. 2019 Nov 22. doi: 10.1007/s40520-019-01414-0. [Epub ahead of print]

Vaccination with (1-11)E2 in alum efficiently induces an antibody response to β-amyloid without affecting brain β-amyloid load and microglia activation in 3xTg mice.

Author information

1
Istituto di Genetica e Biofisica Adriano Buzzati Traverso (IGB), CNR, Naples, Italy.
2
Deutsches Zentrum fur Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
3
Università degli Studi di Verona Dipartimento di Medicina Sezione di Patologia Generale, Verona, Italy.
4
Istituto di Biochimica e Biologia Cellulare (IBBC), CNR, Naples, Italy.
5
Istituto di Genetica e Biofisica Adriano Buzzati Traverso (IGB), CNR, Naples, Italy. antonella.prisco@igb.cnr.it.

Abstract

Immunization against β-amyloid (Aβ) is pursued as a possible strategy for the prevention of Alzheimer's disease (AD). In clinical trials, Aβ 1-42 proved poorly immunogenic and caused severe adverse effects; therefore, safer and more immunogenic candidate vaccines are needed. Multimeric protein (1-11)E2 is able to induce an antibody response to Aβ, immunological memory, and IL-4 production, with no concomitant anti-Aβ T cell response. Antisera recognize Aβ oligomers, protofibrils, and fibrils. In this study, we evaluated the effect of prophylactic immunization with three doses of (1-11)E2 in alum in the 3xTg mouse model of AD. Immunization with (1-11)E2 efficiently induced anti-Aβ antibodies, but afforded no protection against Aβ accumulation and neuroinflammation. The identification of the features of the anti-Aβ immune response that correlate with the ability to prevent Aβ accumulation remains an open problem that deserves further investigation.

KEYWORDS:

Alzheimer’s disease; Antibody response; Immunization; β-amyloid

PMID:
31758499
DOI:
10.1007/s40520-019-01414-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center